The association between age and long-term quality of life after curative treatment for prostate cancer: a cross-sectional study
Sletten, Reidun; Christiansen, Ola B.; Oldervoll, Line Merethe; Åstrøm, Lennart; Skjellegrind, Håvard Kjesbu; Saltyte Benth, Jurate; Kirkevold, Øyvind; Bergh, Sverre; Grønberg, Bjørn Henning; Rostoft, Siri; Bye, Asta; Mork, Paul Jarle; Slaaen, Marit
Journal article, Peer reviewed
Published version
![Thumbnail](/ntnu-xmlui/bitstream/handle/11250/3142990/document.pdf.jpg?sequence=6&isAllowed=y)
View/ Open
Date
2024Metadata
Show full item recordCollections
Abstract
Objective: We aimed to investigate the associations between age at radical prostate cancer treatment and long-term global quality of life (QoL), physical function (PF), and treatment-related side effects.
Material and Methods: This single-center, cross-sectional study included men treated for localized prostate cancer with robotic-assisted radical prostatectomy (RARP) or external beam radiotherapy (EBRT) in 2014–2018. Global QoL and PF were assessed by the European Organisation of Research and Treatment in Cancer Quality of life Questionnaire-C30 (QLQ-C30), side effects by the Expanded Prostate Cancer Index Composite (EPIC-26). Adjusted linear regression models were estimated to assess associations between age (continuous variable) at treatment and outcomes. QLQ-C30 scores were compared to normative data after dividing the cohort in two groups, <70 years and ≥70 years at treatment.
Results: Of 654 men included, 516 (79%) had undergone RARP, and 138 (21%) had undergone EBRT combined with androgen deprivation therapy for 93%. Mean time since treatment was 57 months. Median age at treatment was 68 (min–max 44–84) years. We found no statistically significant independent association between age at treatment and global QoL, PF or side effects, except for sexual function (regression coefficient [RC] −0.77; p < 0.001) and hormonal/vitality (RC 0.30; p = 0.006) function. Mean QLQ-C30 scores were slightly poorer than age-adjusted normative scores, for men <70 years (n = 411) as well as for men ≥70 years (n = 243) at treatment, but the differences were not beyond clinical significance.
Conclusions: In this cohort of prostate cancer survivors, age at treatment had little impact on long-term QoL and function. Due to the cross-sectional design, short term impact or variation over time cannot be ruled out.